Caribou Biosciences Stock Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Source: Yahoo Finance
- Market Volatility: Caribou Biosciences (CRBU) is listed among the 7 most volatile stocks under $5 for day trading, indicating significant investor interest and potential short-term trading opportunities in this low-priced stock segment.
- Sales Potential Forecast: Clear Street projects that Caribou's CB-011 may reach peak sales of $734 million by 2040, despite a low 20% chance of success, highlighting the balance of market potential against clinical risks.
- Rating and Price Target: On February 2, 2026, Clear Street initiated coverage of Caribou with a 'Buy' rating and a $13 price target, primarily based on its upcoming CAR-T program, reflecting market confidence in the company's future developments.
- Industry Dynamics: On January 6, 2026, BofA lowered Caribou's price target from $8 to $6 while maintaining a 'Buy' rating, indicating concerns over durability amidst a broader reset in U.S. biopharma valuations, which may affect investor sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRBU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRBU
Wall Street analysts forecast CRBU stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.640
Low
6.00
Averages
8.00
High
10.00
Current: 1.640
Low
6.00
Averages
8.00
High
10.00
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. The Company is dedicated to developing transformative therapies for patients with devastating diseases. The Company's chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Vispa-cel is an allogeneic anti-CD19 CAR-T cell therapy that has been evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy that is being evaluated in patients with relapsed or refractory multiple myeloma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GT Biopharma Advances NK Cell Therapy with TriKE Platform
- Rise of NK Cell Therapy: GT Biopharma focuses on its TriKE platform to provide scalable, lower-toxicity cancer treatment options, addressing the limitations of T-cell therapies in solid tumors, which is expected to significantly enhance patient treatment experiences.
- Significant Clinical Progress: By 2026, GT Biopharma has advanced three TriKE candidates into clinical stages, with GTB-5550 receiving FDA approval and initiating Phase 1 trials targeting B7-H3 protein in solid tumors, showcasing its potential in treating refractory cancers.
- Massive Market Opportunity: GT Biopharma highlights that the global solid tumor market could reach hundreds of billions of dollars, with B7-H3 being an attractive target due to its broad expression across many common and hard-to-treat solid cancers, indicating a strong unmet medical need for its products.
- Complex Competitive Landscape: GT Biopharma faces fierce competition in NK cell biology from companies like Fate Therapeutics and Nkarta; despite being smaller, its unique TriKE platform and clinical advancements position it well within the rapidly evolving biotech sector.
See More
GT Biopharma Advances NK Cell Therapy with TriKE Platform
- Rise of NK Cell Therapy: GT Biopharma focuses on its TriKE platform to harness NK cells, aiming to provide scalable cancer treatment solutions that are expected to significantly reduce costs and toxicity, addressing the market's demand for safer therapies.
- Significant Clinical Progress: As of 2026, GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 receiving FDA clearance and initiating a Phase 1 trial targeting B7-H3 positive tumors, showcasing potential in the solid tumor space.
- Massive Market Opportunity: The company highlights that the global solid tumor market could reach hundreds of billions of dollars, with B7-H3 being an attractive target due to its broad expression across many difficult-to-treat cancers, presenting substantial commercial value and market appeal.
- Intense Competitive Landscape: While GT Biopharma is actively pursuing NK cell biology, it faces challenges from larger competitors like Fate Therapeutics, which has stronger capital and technological capabilities in cell therapy, indicating that market competition will continue to intensify.
See More
Caribou Biosciences to Present Key Research at EHA Meeting
- Clinical Trial Highlights: Caribou Biosciences will present two significant studies at the 2026 European Hematology Association Annual Meeting, focusing on vispa-cel and CB-011, showcasing their potential in treating relapsed hematologic malignancies, which may drive further advancements in the biopharmaceutical sector.
- ANTLER Trial Insights: In the ANTLER phase 1 clinical trial, 84 patients received vispa-cel treatment, with a recommended phase 2 dose of 80x106 CAR-T cells, demonstrating long-term durability of a single dose, potentially offering new treatment options for patients with relapsed B-cell non-Hodgkin lymphoma.
- CaMMouflage Trial Progress: CB-011 is being evaluated in the CaMMouflage phase 1 clinical trial involving 48 patients, utilizing various dosing and lymphodepletion regimens, indicating its potential application in relapsed multiple myeloma, which may provide new hope for patients.
- FDA Designations: Both vispa-cel and CB-011 have received FDA's Regenerative Medicine Advanced Therapy, Fast Track, and Orphan Drug designations, underscoring their clinical significance and potential market value, which could lead to substantial commercial opportunities for Caribou.
See More
Caribou Biosciences' CAR-T Therapy Receives FDA RMAT Designation
- FDA Designation Milestone: Caribou Biosciences' CAR-T cell therapy, CB-011, has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, marking a significant milestone in the treatment of relapsed or refractory multiple myeloma.
- Clinical Trial Results: Currently undergoing a Phase 1 trial named CaMMouflage, CB-011 has shown a remarkable 92% overall response rate in a review of 12 BCMA-naïve patients, indicating the therapy's potential effectiveness.
- Accelerated Approval Benefits: With the RMAT designation, Caribou can benefit from the FDA's priority and rolling review processes, potentially expediting the market entry of CB-011 and leading to quicker returns for the company.
- Positive Market Reaction: Following the FDA announcement, Caribou's stock rose approximately 9% in premarket trading, reflecting investor optimism regarding the prospects of its CAR-T therapy and further solidifying the company's position in the cell therapy market.
See More
Caribou Biosciences Receives FDA RMAT Designation for CB-011
- Promising Clinical Data: Caribou Biosciences' CB-011 demonstrated a 92% overall response rate (ORR) and a 75% complete response (CR) rate in a cohort of 12 BCMA-naïve patients with relapsed or refractory multiple myeloma, indicating significant potential to transform treatment outcomes for patients.
- FDA Designation Accelerates Development: The FDA granted RMAT designation to CB-011, aimed at expediting its development process, highlighting the therapy's importance in addressing the unmet medical needs of multiple myeloma patients and potentially accelerating its path to market.
- Favorable Safety Profile: CB-011 exhibited a manageable safety profile with no cases of graft-versus-host disease reported, although 80% of patients experienced neutropenia; this positive safety data supports its future clinical applications and market acceptance.
- Positive Future Outlook: Caribou plans to report longer follow-up data in 2026 and engage in discussions with the FDA regarding the future clinical development of CB-011, reflecting the company's confidence in the therapy and its potential market impact.
See More
Caribou Bioscience Q4 Earnings Beat Expectations
- Earnings Highlights: Caribou Bioscience reported a Q4 GAAP EPS of -$0.28, beating expectations by $0.04, indicating an improvement in profitability despite still being in the red.
- Revenue Surge: The company achieved Q4 revenue of $3.94M, representing an 89.4% year-over-year increase and surpassing market expectations by $1.98M, reflecting strong product demand and enhanced market acceptance.
- Cash Position: As of December 31, 2025, Caribou reported $142.8 million in cash, cash equivalents, and marketable securities, down from $249.4 million in 2024, highlighting challenges in cash management.
- Future Outlook: Caribou expects its current cash reserves to fund its operational plans, including dose expansion for CB-011 and startup activities for the planned vispa-cel pivotal trial, projected to last into the second half of 2027, demonstrating confidence in future growth.
See More
GT Biopharma Advances NK Cell Therapy with TriKE Platform
- Rise of NK Cell Therapy: GT Biopharma focuses on its TriKE platform to provide scalable, lower-toxicity cancer treatment options, addressing the limitations of T-cell therapies in solid tumors, which is expected to significantly enhance patient treatment experiences.
- Significant Clinical Progress: By 2026, GT Biopharma has advanced three TriKE candidates into clinical stages, with GTB-5550 receiving FDA approval and initiating Phase 1 trials targeting B7-H3 protein in solid tumors, showcasing its potential in treating refractory cancers.
- Massive Market Opportunity: GT Biopharma highlights that the global solid tumor market could reach hundreds of billions of dollars, with B7-H3 being an attractive target due to its broad expression across many common and hard-to-treat solid cancers, indicating a strong unmet medical need for its products.
- Complex Competitive Landscape: GT Biopharma faces fierce competition in NK cell biology from companies like Fate Therapeutics and Nkarta; despite being smaller, its unique TriKE platform and clinical advancements position it well within the rapidly evolving biotech sector.
See More
GT Biopharma Advances NK Cell Therapy with TriKE Platform
- Rise of NK Cell Therapy: GT Biopharma focuses on its TriKE platform to harness NK cells, aiming to provide scalable cancer treatment solutions that are expected to significantly reduce costs and toxicity, addressing the market's demand for safer therapies.
- Significant Clinical Progress: As of 2026, GT Biopharma has advanced three TriKE candidates into the clinic, with GTB-5550 receiving FDA clearance and initiating a Phase 1 trial targeting B7-H3 positive tumors, showcasing potential in the solid tumor space.
- Massive Market Opportunity: The company highlights that the global solid tumor market could reach hundreds of billions of dollars, with B7-H3 being an attractive target due to its broad expression across many difficult-to-treat cancers, presenting substantial commercial value and market appeal.
- Intense Competitive Landscape: While GT Biopharma is actively pursuing NK cell biology, it faces challenges from larger competitors like Fate Therapeutics, which has stronger capital and technological capabilities in cell therapy, indicating that market competition will continue to intensify.
See More
Caribou Biosciences to Present Key Research at EHA Meeting
- Clinical Trial Highlights: Caribou Biosciences will present two significant studies at the 2026 European Hematology Association Annual Meeting, focusing on vispa-cel and CB-011, showcasing their potential in treating relapsed hematologic malignancies, which may drive further advancements in the biopharmaceutical sector.
- ANTLER Trial Insights: In the ANTLER phase 1 clinical trial, 84 patients received vispa-cel treatment, with a recommended phase 2 dose of 80x106 CAR-T cells, demonstrating long-term durability of a single dose, potentially offering new treatment options for patients with relapsed B-cell non-Hodgkin lymphoma.
- CaMMouflage Trial Progress: CB-011 is being evaluated in the CaMMouflage phase 1 clinical trial involving 48 patients, utilizing various dosing and lymphodepletion regimens, indicating its potential application in relapsed multiple myeloma, which may provide new hope for patients.
- FDA Designations: Both vispa-cel and CB-011 have received FDA's Regenerative Medicine Advanced Therapy, Fast Track, and Orphan Drug designations, underscoring their clinical significance and potential market value, which could lead to substantial commercial opportunities for Caribou.
See More
Caribou Biosciences' CAR-T Therapy Receives FDA RMAT Designation
- FDA Designation Milestone: Caribou Biosciences' CAR-T cell therapy, CB-011, has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, marking a significant milestone in the treatment of relapsed or refractory multiple myeloma.
- Clinical Trial Results: Currently undergoing a Phase 1 trial named CaMMouflage, CB-011 has shown a remarkable 92% overall response rate in a review of 12 BCMA-naïve patients, indicating the therapy's potential effectiveness.
- Accelerated Approval Benefits: With the RMAT designation, Caribou can benefit from the FDA's priority and rolling review processes, potentially expediting the market entry of CB-011 and leading to quicker returns for the company.
- Positive Market Reaction: Following the FDA announcement, Caribou's stock rose approximately 9% in premarket trading, reflecting investor optimism regarding the prospects of its CAR-T therapy and further solidifying the company's position in the cell therapy market.
See More
Caribou Biosciences Receives FDA RMAT Designation for CB-011
- Promising Clinical Data: Caribou Biosciences' CB-011 demonstrated a 92% overall response rate (ORR) and a 75% complete response (CR) rate in a cohort of 12 BCMA-naïve patients with relapsed or refractory multiple myeloma, indicating significant potential to transform treatment outcomes for patients.
- FDA Designation Accelerates Development: The FDA granted RMAT designation to CB-011, aimed at expediting its development process, highlighting the therapy's importance in addressing the unmet medical needs of multiple myeloma patients and potentially accelerating its path to market.
- Favorable Safety Profile: CB-011 exhibited a manageable safety profile with no cases of graft-versus-host disease reported, although 80% of patients experienced neutropenia; this positive safety data supports its future clinical applications and market acceptance.
- Positive Future Outlook: Caribou plans to report longer follow-up data in 2026 and engage in discussions with the FDA regarding the future clinical development of CB-011, reflecting the company's confidence in the therapy and its potential market impact.
See More
Caribou Bioscience Q4 Earnings Beat Expectations
- Earnings Highlights: Caribou Bioscience reported a Q4 GAAP EPS of -$0.28, beating expectations by $0.04, indicating an improvement in profitability despite still being in the red.
- Revenue Surge: The company achieved Q4 revenue of $3.94M, representing an 89.4% year-over-year increase and surpassing market expectations by $1.98M, reflecting strong product demand and enhanced market acceptance.
- Cash Position: As of December 31, 2025, Caribou reported $142.8 million in cash, cash equivalents, and marketable securities, down from $249.4 million in 2024, highlighting challenges in cash management.
- Future Outlook: Caribou expects its current cash reserves to fund its operational plans, including dose expansion for CB-011 and startup activities for the planned vispa-cel pivotal trial, projected to last into the second half of 2027, demonstrating confidence in future growth.
See More
